Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1190B CAR-T in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT07032324Phase 1Not yet recruiting
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT-1190B in B-cell non-Hodgkin lymphoma. Primary endpoints: Adverse Events at 12 months and Maximum Tolerated Dose at 28 days. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
CT-1190B
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07032324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07032324.